Table 1. Patient and Clinical Characteristics by total cMET and phospho-cMET levels.

	Overall (N=257)		cMET					p-cMET
			High cMET (>0) (N=181)		Low cMET (≤0) (N=76)			High p-cMET (>0.35) (N=123)		Low p-cMET (≤0.35) (N=134)
	N	%	N	%	N	%	P	N	%	N	%	P
Age
≤ 50	128	49.8	83	45.9	45	59.2	0.069	49	39.8	79	59.0	0.003
>50	129	50.2	98	54.1	31	40.8		74	60.2	55	41.0
Stage
I	8	3.1	4	2.2	4	5.3	0.426	2	1.6	6	4.5	0.391
II	141	55.3	43	56.4	40	52.6		67	54.9	74	55.6
III	106	41.6	39	41.3	32	42.1		53	43.4	53	39.8
Grade
1	12	4.7	9	5.1	3	4.0	0.473	9	7.5	3	2.3	0.046
2	73	28.9	55	30.9	18	24.0		39	32.5	34	25.6
3	168	66.4	114	64.0	54	72.0		72	60.0	96	72.2
Chemotherapy
Anthracycline based	17	6.7	11	6.2	6	7.9	0.228	10	8.3	7	5.3	0.214
Taxane based	21	8.3	16	16.9	5	6.6		10	8.3	11	8.3
Anthracycline & Taxane	180	70.9	121	68.1	59	77.6		79	65.3	101	75.9
No Chemotherapy	36	14.1	30	16.8	6	7.9		22	18.2	14	10.5
Hormone Therapy
Yes	107	40.5	70	38.7	37	48.7	0.178	59	48.0	48	35.8	0.065
No	150	59.5	111	61.3	39	51.3		64	52.0	86	64.2
Radiation Therapy
Yes	164	63.8	108	59.7	56	73.7	0.046	79	64.2	85	63.4	0.998
No	93	36.2	73	40.3	20	26.3		44	35.8	49	36.6
Subtype
HER2-positive	53	20.6	40	22.1	13	17.1	0.079	25	20.3	28	20.9	0.064
HR-positive	140	54.5	103	56.9	37	48.7		75	61.0	65	48.5
Triple Negative	64	24.9	38	31.0	26	34.2		23	18.7	41	30.6

cMET: Total cMET, p-cMET: Phospho-cMET, HR-positive: Hormone receptor positive